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Since their introduction in the middle of the 20th Century,
randomised trials of sufficiently large size have provided
reliable assessments of the safety and efficacy of treat-
ments that have produced substantial improvements in
health. During the past decade, however, increasingly
onerous (albeit well-meaning) regulation and related
bureaucracy have made clinical trials much more difficult
and costly to conduct. The impact of these large increases
in costs and effort is that many existing and novel inter-
ventions are not being evaluated, or the trials that are con-
ducted are smaller and less informative than they might
otherwise be. The negative effect of these obstacles on the
emergence of reliable evidence about the safety and effi-
cacy of treatments affects the care of people not just in
developed countries but also in developing countries
where resources are more limited and the burden of dis-
ease is large. Hence, there is an urgent need for major
changes to procedures for the initiation, conduct, monitor-
ing and safety reporting of clinical trials such that they are
more proportionate to the risks of doing a trial compared
with the risks of not doing it. Unless radical improvements
are now made to the regulatory environment, the huge
potential of clinical trials to assess the safety and efficacy
of new and existing treatments and, thereby, to produce
substantial improvements in health care and public health
will not be fulfilled.
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